Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.

Diabetes & vascular disease research Pub Date : 2023-11-01 DOI:10.1177/14791641231197114

Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Abolfazl Qezelgachi, Kiana Seifouri, Armin Pesaran Afsharian, Farzad Sheikhzadeh, Atefe Poursalehi, Fateme Sadat Fani Sadrabadi, Mehrnush Saghab Torbati, Mohaddese Ramezanzade, Goharsharieh Alishiri, Arina Ansari, Emad Zare Dehabadi, Saeed Karimi Matloub, Zahra Sheikh, Niloofar Deravi, Saba Mehrtabar, Fatemeh Chichagi, Neda Faal Hamedanchi, Mohammadreza Arzaghi, Mahla Asadi, Parisa Alsadat Dadkhah, Akram Ansari

{"title":"Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review.","authors":"Mohammad Sadra Gholami Chahkand, Fatemeh Esmaeilpour Moallem, Abolfazl Qezelgachi, Kiana Seifouri, Armin Pesaran Afsharian, Farzad Sheikhzadeh, Atefe Poursalehi, Fateme Sadat Fani Sadrabadi, Mehrnush Saghab Torbati, Mohaddese Ramezanzade, Goharsharieh Alishiri, Arina Ansari, Emad Zare Dehabadi, Saeed Karimi Matloub, Zahra Sheikh, Niloofar Deravi, Saba Mehrtabar, Fatemeh Chichagi, Neda Faal Hamedanchi, Mohammadreza Arzaghi, Mahla Asadi, Parisa Alsadat Dadkhah, Akram Ansari","doi":"10.1177/14791641231197114","DOIUrl":null,"url":null,"abstract":"Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"20 6","pages":"14791641231197114"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685788/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & vascular disease research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/14791641231197114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes-the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy.

Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention.

Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy.

Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.

查看原文本刊更多论文

脂蛋白(a)作为2型糖尿病患者糖尿病视网膜病变的预测因子:一项系统综述。

背景:脂蛋白a (LP(a))是一种ldl样脂蛋白，被认为是心血管疾病的危险因素，与2型糖尿病患者的糖尿病视网膜病变存在争议性关联。本系统综述旨在严格评估LP(a)与糖尿病视网膜病变之间的关联。方法:全面检索PubMed、Scopus、Google Scholar电子数据库，对相关研究进行系统综述。我们使用截至2022年8月发表的英国观察性、病例对照和前瞻性队列研究，包括2型糖尿病患者作为人群，糖尿病视网膜病变作为结果，LP(a)作为干预。结果:本系统综述纳入17项相关研究，共纳入4688例糖尿病患者。虽然在13项研究中，脂蛋白(a)被认为是糖尿病视网膜病变的危险因素，但只有3项研究报告没有证据表明两者之间存在关系。此外，另一项研究显示LP(a)与糖尿病视网膜病变之间的关系好坏参半。结论:2型糖尿病患者高血清脂蛋白(a)被认为是糖尿病视网膜病变的危险因素。然而，仍需要进一步的大规模队列研究来验证这一发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & vascular disease research

自引率

0.00%

发文量